Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The moderators shouldn't have to do anything. It's members of the boards that are fueling the fire of non-TITXF posts being posted and also going over to TRXC and posting pointless conversation. There's benefits and advantages to both companies. Let's keep the conversation to relevant and educational info only for investor diligence and education.
Great results this morning - Looking for more to come and for us to keep climbing.
Sounds like they sold a robot(s) to a customer in that region and it's now being reverse engineered by a company. Happens a ton over there for all types of devices. Not only hurts their market share in that region, but it would also hurt Titan. Can't imagine what else this rep would be referring to.
TransEnterix, Inc. to present at the Raymond James & Associates' 36th Annual Institutional Investors Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC) announced today that Todd M. Pope, President and Chief Executive Officer, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Raymond James & Associates' 36th Annual Institutional Investors Conference at the JW Marriott Grande Lakes Hotel in Orlando, Florida. The presentation is scheduled to take place at 7:30 am Eastern Time on Monday, March 2, 2015.
To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the company's website.
http://ir.transenterix.com/releasedetail.cfm?ReleaseID=896841
Intuitive has a very close eye on Titan and other players in this market. Getting a device to market slower than a competitor means a loss of market share and therefore revenue. Intuitive wants its device to the market first and ensure it meets all the needs of the customers.
While they will get to the market first, Titan has the advantage over Intuitive in that it meets the the growing needs of many hospitals (price, mobility, snake-arm design, etc) and can eat into Intuitive market share.
As ddreturns mentioned, cannibalizing the market share from those large companies is minor due to their diversification. Obviously many large companies are itching to get into this space and take some market share from Intuitive. Unless they are developing robots on the back end, this will likely come through M&A - much better ROI than developing your own robotic divisions along with all the R&D and clinical trial costs. Titan has the technology and is a ripe contender for this.
A lot of M&A activity is being shifted to later-stage companies (FDA) and inclusive of CE market. Small amount is occurring for developmental stage companies. I don't think Titan will go it alone; a large medical device company will pick up Titan right around or after CE mark. It will be a company that's hungry to beat out Intuitive from their market share.
Check out this SVB market report if you haven't already http://bit.ly/1ydUvMG
The last few releases were in the am +/- 1 hour after open. Was hoping we would see the report around close or the same time the BTIG info was released yesterday... not looking like it.
Neurovascular. I am not a practicing physician though - Sponsor side.
Enjoyed reading this discussion - Totally out of the scope of therapies I deal with so enjoy learning something from you guys.
Let's see more discussions like this instead of bullshit on this board.
Noemotion - thanks for sharing this article with us. Great to see evidence being published supporting the use of robotic assisted surgeries and advantage over increasingly inferior procedures.
I hope everyone that comes across articles like this will post for other readers to view and explore supported findings.
I could not even get through reading the article with how poorly designed and distracting that site is.
This is good to hear. Definitely smart money backing this company both institutionally and on the VC side.
Does anyone have any market analysis papers/articles for the robotics industry?
I thought the same thing today, but only for a second. Luckily I bought a couple thousand on the low and increased my position today as well. Most of my cost basis in the high 1.9s and low 2s, so anything below this point is a bargain compared to where I was content at buying before.
Brokerages Give $6.05 Average Price Target to Transenterix (NASDAQ:TRXC)
http://www.dakotafinancialnews.com/zacks-brokerages-give-6-05-average-price-target-to-transenterix-nasdaqtrxc/31015/
A lot of things are up. Excited for the next few months.
Exactly... been slowly buying every few days. If you're long on Titan, there's no reason you should be missing this buying opportunity.
There are a lot of institutions invested in TRXC; a lot that know what is going on behind the scenes and a lot of companies that the public is not aware of. Can't expand more, but it's looking good for TRXC. I'm gunning for equal success between TITXF and TRXC and am equally invested in both.
I like this a lot. Some big money in the game now and great to hear they are on track for 510(k) submission. This should go very smoothly. Looking forward to 2015.
Nice move today boys! Let's keep it up.
Does TITXF being a Passive Foreign Investment Company affect this tax year or only 2013? Have you guys in the states seen any issues with this?
I briefly read Point's collection of questions to ask management, but he writes for SA? If so, he probably won't be back until he publicly publishing everyone's questions and answers or an article on SA that will actually bring in money rather than posting it for free.
I own both - about equal amounts, maybe a little more TITXF at this point. Wish I had funds to add to my position at these lows I'd be buying both companies up right now.
This last couple days on the board truly showed what type of person each poster is. It made it very easy to pick out those with hidden agendas (if it wasn't obvious already) trying to lower and increase PPS by superficial means. Nice to see that a majority of posters I enjoy kept their heads on and remained strong to their typical belief in Titan. As for the others, their posts will be taken with a grain of salt if not ignored all together.
After trashing Titan for the last few days saying it will crumble to well below a dollar and no news for over a year and you're now back in?
Reimbursement is a huge key here. With the way healthcare is moving medical device companies are shifting their resources to get maximize their reimbursement for their products. If insurance isn't paying, customers aren't buying. This can make or break a product.
Reimbursement is a huge key here. With the way healthcare is moving medical device companies are shifting their resources to get maximize their reimbursement for their products. If insurance isn't paying, customers aren't buying. This can make or break a product.
Might as well invest in actual 18k gold. If you look at the amount of gold in a rolex vs. the amount of raw gold you're vastly overpaying for gold by buying the Rolex. Granted the price of gold will have little influence on the price of a gold Rolex. However, you do see little depreciation on a Rolex and the chance of appreciation.
I buy my watches to enjoy, but it's nice knowing the can be resold years down the line for little to none below what I paid for them.
I guess we should have bought the platinum Daytona or that WG GMT Pepsi is looking pretty good right now.
Where was Hargrove's daughter's salary and new salary posted? I don't believe I saw it in the MD&A, maybe I am missing it though.
What is the background on this stapler? I see that it is Dr. Swanstrom's stapler, but do Titan and Cardica have a partnership or exclusivity on this besides having Dr. Swanstrom on the board of surgeons? I must have missed this news if someone could brief me.
I am all in still - I am long in this stock so these fluctuations hurt but long term don't matter much to me.
Wish I could be adding to my position right now. Recently invested in some other healthcare stocks and have no free funds right now.
I can echo the sentiment that Elcaribes is the real deal. Of all requests of members on this board to back their claims, he is the only one that I have seen pull through.
I hope others begin to do the same and focus posting only credible information (Ha!).
You are correct - I meant to phrase as finalizing their working prototypes.
I think it has a lot to do with everything. Before they brought on Ximedica, their board of surgeons, new executives, changes in PR firms, etc they were basically going at it alone. The more and more they discuss with these groups of people in addition to the changing landscape of the market could result in the delay that Titan is going through. Perhaps their previous prototype/indication was to be successful in the market at the time they conceived it several years ago. The industry is changing quickly and new technology, devices, and methods of disease treatment are changing daily. A strong response from the "industry" (as I refer to those groups recently brought on) is most likely the driving force behind this.
Remember, Titan is essentially in startup phase still and do not have a working prototype. The only difference is they have an exceptionally strong team of executives, a good product development firm, and a strong array of patents and device plans to produce an incredible device. Not to mention they have the funding to go to market!!
It's not all about the share price at this point as most of you tend to think, they're more focused on their daily activities and bringing this to market. There's a ton more companies in their space (regardless of therapy) finding investors, doing R&D, and trying to produce devices, and Titan is well ahead of the game; granted, the majority of these companies are not public at this stage.
Exactly - you all need to be thinking long term.
Just last week everyone was long and praising Titan's partnerships, board of surgeons, etc. Don't you think all of these elements have come together to provide the outcome for more indications with evidence backing this decision? They asked their advisors, board, customers, etc and they responded - they would be stupid to go to market with a limited device when a majority of their customers are looking for more.
Sure, it could always be used off-label, but the device could not be marketed that way. Although there's a delay, they are and we are much better off with them seeing a 1 year delay and coming out with a killer product than producing a product with no results.
Have you all considered the timeline being extremely conservative?
They obviously don't want to put all their cards on the table. As much as they should be informing shareholders, they want to have a conservative timeline if they run into problems and more importantly don't want competitors to know exactly when their product will hit the market.
Think about what the competitors and ISRG are assuming based off this timeline. Then imagine mid to late FY15 this timeline shifts to ~ 0.5 to 1 year earlier because of great prototype/design results or fast tracked regulatory submissions. What competitors were planning to occur in 2 years is now happening at 1 - 1.5 years and they'll have to react accordingly to hold their market share or race to get their device to the market.
Just a consideration.
Thanks for posting the link to this.
Exactly. They're right on target for their development and prototype milestones as stated in the MD&A and as many of has had hoped and assumed they would be. Of course the clinical trials, indications, and regulatory approvals/launch are up in the air. This has been said by myself and many others over the course of the last 6 months.
Setting up the proper indications, designing your protocols and clinical trials and getting regulatory approvals is a task in itself and will likely see delays. I'm just glad they have made the business decision to expand indications now and not when they are invested into the clinical trial stage.
Very nicely put. This is only a minor set back for Titan - I hate to even call it a set back. They're increasing their indications which will allow them to increase their market share. Sure this pushes the timeline back a bit, but that's required with the R&D and clinical aspect that needs to go into this. They are on track with their prototype development and design verification and they have nice funding to do so.
Intuitive earnings call today.